On Friday, Stichting Preferred Shares Mylan, an independent foundation established in the Netherlands, announced that it would exercise its full call option to purchase 488,388,431 preferred shares in Mylan.
The Food and Drug Administration announced Friday that it approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and cirrhosis.
America’s biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.
The average lost time worker's compensation claim for workers using opioid painkillers can total as much as $117,000 — 900% higher than the cost for workers who do not take opioid painkillers, the National Safety Council says.
Otsuka Pharmaceutical and H. Lundbeck A/S announced Friday that their new medication Rexulti (brexpiprazole) had been approved by the Food and Drug Administration as an adjunctive treatment for major depressive disorder (MDD) and a treament for schizophrenia.